McGetrick J J, Jampol L M, Goldberg M F, Frenkel M, Fiscella R G
Arch Ophthalmol. 1983 Jul;101(7):1031-3. doi: 10.1001/archopht.1983.01040020033003.
Forty-eight patients (49 eyes) had nonperforating traumatic hyphema. Twenty-eight patients (28 eyes with hyphema) received oral aminocaproic acid, an antifibrinolytic agent, in a dosage of 100 mg/kg every four hours for five days, up to a maximum daily dose of 30 g. Twenty patients (21 eyes with hyphema) received placebo in an identical regimen. One eye treated with aminocaproic acid rebled; seven eyes receiving the placebo rebled. The results of this study show a statistically significant reduction in the incidence of secondary hemorrhage in the patients receiving aminocaproic acid.
48例患者(49只眼)患有非穿通性外伤性前房积血。28例患者(28只眼前房积血)接受口服抗纤溶药物氨基己酸治疗,剂量为每4小时100mg/kg,共5天,最大日剂量为30g。20例患者(21只眼前房积血)接受相同疗程的安慰剂治疗。接受氨基己酸治疗的1只眼再次出血;接受安慰剂治疗的7只眼再次出血。本研究结果显示,接受氨基己酸治疗的患者继发性出血发生率有统计学意义的降低。